Key result
In elderly patients with atrial fibrillation, the risk of acetylsalicylic acid use may outweigh its benefits, and combining antiplatelets with anticoagulants increases bleeding without reducing stroke.
Why the study?
Does antiplatelet therapy improve stroke prevention without excessive bleeding risk compared to anticoagulants in elderly patients with atrial fibrillation?
Does antiplatelet therapy improve stroke prevention without excessive bleeding risk compared to anticoagulants in elderly patients with atrial fibrillation?
Antiplatelet therapy, particularly acetylsalicylic acid, may carry bleeding risks that outweigh benefits in elderly AF patients, reinforcing guidelines that favor anticoagulants.
Answers are grounded in this paper and cite their sources.
May support avoiding aspirin in elderly AF on OAC; leaves open need for confirmatory RCTs.
Current guidelines for the management of atrial fibrillation (AF) recommend using anticoagulants as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often prescribed to elderly patients. Review of clinical and pharmacoepidemiological studies allows us to conclude that risk associated with acetylsalicylic acid (ASA) use in patients ≥75 years can overweigh its potential benefit. Other antiplatelet drugs are poorly studied in patients with AF. Dual antiplatelet therapy (ASA + clopidogrel) can be prescribed to elderly patients with cardiovascular comorbidity who are deemed unsuitable candidates for anticoagulant therapy for reasons other than bleeding risk or those who refuse to take oral anticoagulants. Combined therapy of antiplatelet drugs with warfarin or new oral anticoagulants results in no reduction in stroke rate compared with anticoagulant monotherapy but is associated with increased risk of bleeding and can’t be recommended.
No takes yet. Share an insight, caveat, or question.
Ушкалова et al. (2017) conducted a review in Atrial fibrillation. Antiplatelet therapy vs. Anticoagulants was evaluated. In elderly patients with atrial fibrillation, the risk of acetylsalicylic acid use may outweigh its benefits, and combining antiplatelets with anticoagulants increases bleeding without reducing stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: